MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.

BACKGROUND Glioblastoma multiforme (GBM) is a form of highly malignant brain tumour. Temozolomide (TMZ) is the standard agent for GBM, but TMZ-resistance is common and accounts for many treatment failures. MicroRNA-21 (miR-21) is a non-coding RNA that plays critical roles in many biological processes in cancer, including chemoresistance. We investigated miR-21 expression and the effect of miR-21 inhibition in GBM with acquired TMZ resistance. MATERIALS AND METHODS Human GBM cell line D54MG was treated with TMZ chronically to develop a chemoresistant subclone. MiR-21 inhibition was achieved by transfection with anti-mir-21 oligonucleotide. RESULTS Chronic TMZ exposure resulted in acquired TMZ-resistance and elevated miR-21 expression. Concomitant treatment with miR-21 inhibitor and TMZ resulted in a significantly higher apoptotic rate than TMZ treatment alone. CONCLUSION MiR-21 may have a potential for use as a biomarker of acquired TMZ resistance. MiR-21 inhibition can be further explored as a potential chemotherapy adjunct in the treatment of TMZ-resistant GBM.

[1]  Masayuki Watanabe,et al.  Serum microRNA‐21 is a novel biomarker in patients with esophageal squamous cell carcinoma , 2012, Journal of surgical oncology.

[2]  Philip J. R. Day,et al.  LABORATORY INVESTIGATION- HUMAN/ANIMAL TISSUE Protein , 2022 .

[3]  Y. You,et al.  MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. , 2011, International journal of oncology.

[4]  Benjamin Purow,et al.  The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma? , 2011, Journal of Neuro-Oncology.

[5]  M. Chopp,et al.  Functional microRNA is transferred between glioma cells. , 2010, Cancer research.

[6]  Keiji Suzuki,et al.  miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. , 2010, Cancer letters.

[7]  Wei Zhang,et al.  Targeting miR-21 in glioma: a small RNA with big potential , 2010, Expert opinion on therapeutic targets.

[8]  Lei Shi,et al.  MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity , 2010, Brain Research.

[9]  J. Rich,et al.  Potential therapeutic implications of cancer stem cells in glioblastoma. , 2010, Biochemical pharmacology.

[10]  Lei Shi,et al.  Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. , 2010, Oncology reports.

[11]  Xi Chen,et al.  The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. , 2010, European journal of cancer.

[12]  J. Schelter,et al.  Reduced seed region-based off-target activity with lentivirus-mediated RNAi. , 2010, RNA.

[13]  Kai Stühler,et al.  Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas , 2010, Brain pathology.

[14]  Lei Han,et al.  MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol , 2010, BMC Cancer.

[15]  P. Northcott,et al.  Normal and oncogenic roles for microRNAs in the developing brain , 2009, Cell cycle.

[16]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[17]  J. Benoit,et al.  Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. , 2009, Biomaterials.

[18]  V. Kouloulias,et al.  Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy; A Review Article , 2009, Molecules.

[19]  Guan-li Huang,et al.  Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. , 2009, Oncology reports.

[20]  Francesco Tomasello,et al.  miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors , 2009, Journal of Neuro-Oncology.

[21]  Vassilis Georgoulias,et al.  Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. , 2008, Clinical chemistry.

[22]  Alice Shapiro,et al.  MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. , 2008, Cancer research.

[23]  T. Wurdinger,et al.  MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators , 2008, Molecular and Cellular Biology.

[24]  H. Allgayer,et al.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.

[25]  A. Shervington,et al.  Chemoresistance in gliomas , 2008, Molecular and Cellular Biochemistry.

[26]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[27]  Shuomin Zhu,et al.  MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)* , 2007, Journal of Biological Chemistry.

[28]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[29]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[30]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[31]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[32]  S. Finkelstein,et al.  Multifaceted resistance of gliomas to temozolomide. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Michálek,et al.  MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. , 2010, Neoplasma.

[34]  L. Tentori,et al.  Recent approaches to improve the antitumor efficacy of temozolomide. , 2009, Current medicinal chemistry.

[35]  A. Chakravarti,et al.  Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. , 2008, Cancer treatment and research.